GALLAGHER, Associate Judge:
Although sparking much debate among legal commentators,1 the issue presented on appeal is one of first impression in this jurisdiction: the liability of a hospital for disease contracted from blood transfusions. Appellant, who sought to recover damages for personal injuries sustained when she incurred hepatitis after a transfusion of blood supplied by Sibley Memorial Hospital, lost at trial on a negligence theory. She asserts on appeal that the trial court erred, as a matter of law, in directing a verdict for the hospital on the theories of breach of implied warranty and strict liability in tort, thus withdrawing those theories from jury consideration. In our view, the judgment must be affirmed, because neither theory applies to the administering of blood transfusions by a hospital.
Appellant was admitted to Sibley Memorial Hospital (the hospital) in November 1974, following complaints of rectal bleeding. While hospitalized she received a transfusion of one unit of blood, ordered by the attending physician. Two months later, in January 1975, she was examined by her physician, who made a clinical diagnosis of hepatitis.2
The unit of blood administered to Miss Fisher, as a Red Cross representative testified, was collected from a volunteer donor in October 1974. At the time of donation, the blood was tested for type and group, as well as for hepatitis and syphilis contamination. The hepatitis test result was negative. The blood unit passed through the blood supply operations at Sibley Hospital and was retested for the hepatitis virus with negative results at the hospital laboratory facility. As was customary, the Red Cross charged a processing fee for the unit of blood which was paid by the hospital. Miss Fisher, in turn, was charged separately on an itemized hospital bill for blood processing and for the actual blood transfused. The charge for the blood was described as a “donor motivation fee” which was refundable if she later donated blood to the hospital.
There was conflicting expert testimony introduced at trial regarding the mode by which the hepatitis virus, Type A, is transmitted. Appellant’s treating physician and an expert medical witness called by appellant at trial both testified that Type A may be transmitted by blood transfusions, although the primary means of transmission is oral, through contaminated food or water. The expert medical witness called by the defendant, a physician affiliated with the hospital, testified that the Type A virus is believed to be transmitted orally, while Type B is linked to injections with contaminated needles and transfusions of impure blood.
Both experts testified, however, that no test will detect the presence of the Type A virus in the donor’s blood. The experts also agreed that an antigen test had been developed which discloses the presence of hepatitis Type B, but it is not totally accurate. Appellant’s medical expert placed the test’s accuracy as to Type B hepatitis at 70%, and at 35% overall accuracy as to carriers of [1132]*1132both types. According to appellee’s expert, the antigen test picks up about 30% of hepatitis carriers.
After argument, the court directed a verdict for defendant on the breach of warranty and strict liability theories, but denied the motion as to the negligence count. The negligence issue was submitted to the jury which returned a verdict for the hospital.
Under D.C.Code 1973, § 28:2-314, an implied warranty of merchantability arises from a contract of sale if the seller is a merchant with respect to the goods sold. Thus, to state a valid cause of action for breach of warranty, plaintiff first must demonstrate that the giving of. a blood transfusion constitutes a sale of goods carrying an implied warranty of fitness for ordinary uses. D.C.Code 1973 § 28:2-314(2)(c). In Perlmutter v. Beth David Hospital, 308 N.Y. 100, 123 N.E.2d 792 (1954), the first case to construe the implied warranty theory as applied to blood transfusions, the court held that plaintiff failed to state a cause of action. It reasoned that a blood transfusion could not be characterized as a product sold to the patient. Rather, the transfusion was a “service” which was part of the overall treatment that plaintiff received from the defendant hospital.
The “sales-service” dichotomy has controlled much of the hepatitis case law subsequent to Perlmutter.3 Its rationale — that blood transfusions are services for which breach of warranty will not lie — was not questioned until 1966 when the Florida Supreme Court in Community Blood Bank Inc. v. Russell, 196 So.2d 115 (Fla.1967), carved out an exception for commercial blood banks. Although the courts of various states have recently gone different ways in the blood transfusion cases,4 the majority are reluctant to apply traditional notions of sales law and the commercial warranty concept to nonprofit hospitals. As the Minnesota Supreme Court persuasively stated in dismissing a hepatitis victim’s suit:
We find it difficult to give literal application of principles of law designed to impose strict accountability in commercial transactions to a voluntary and charitable activity which serves a humane and public health purpose. The activities involved in the transfusion of whole blood, a component of the living body, from one human being to another may be characterized as sui generis in that the sequence of events involve acts common to legal, concepts of both a sale and a service. Moreover, it seems to us that under the facts in the case before us it would be unrealistic to hold that there is an implied warranty as to qualities of fitness of human blood on which no medical or scientific information can be acquired and in respect to which plaintiff’s physician has the same information, knowledge, and experience as the supplier. [Balkowitsch v. Minneapolis War Memorial Blood Bank, Inc., 270 Minn; 151, 132 N.W.2d 805, 811 (1965).]
[1133]*1133We agree with those courts which hold that the furnishing of blood is more in the nature of a service than of a sale of goods. Treating blood transfusions as an incidental service performed by hospitals comports with reality, and with the policies underlying merchantability liability. Although theoretically a seller’s inability to discover defects in the goods he sells is not relevant to a warranty cause of action,5 we cannot ignore the difficulty of detecting hepatitis in blood given the current state of medical knowledge.6 To characterize as a sale the supplying of blood would mean that the hospital, no matter how careful, would be held responsible, virtually as an insurer, if the patient were harmed as a result of impure blood. After balancing the safety of the individual with the interests of the hospital (in light of the absence of an adequate test to determine the presence of hepatitis in the blood) and the public interest in assuring the ready availability of blood for medical treatments, we are reluctant to extend § 2-314 merchantability liability to a nonsale transaction by analogy 7 or by characterizing the transaction as a sale.
Because we view actions for breach of warranty and strict liability in tort8
Free access — add to your briefcase to read the full text and ask questions with AI
GALLAGHER, Associate Judge:
Although sparking much debate among legal commentators,1 the issue presented on appeal is one of first impression in this jurisdiction: the liability of a hospital for disease contracted from blood transfusions. Appellant, who sought to recover damages for personal injuries sustained when she incurred hepatitis after a transfusion of blood supplied by Sibley Memorial Hospital, lost at trial on a negligence theory. She asserts on appeal that the trial court erred, as a matter of law, in directing a verdict for the hospital on the theories of breach of implied warranty and strict liability in tort, thus withdrawing those theories from jury consideration. In our view, the judgment must be affirmed, because neither theory applies to the administering of blood transfusions by a hospital.
Appellant was admitted to Sibley Memorial Hospital (the hospital) in November 1974, following complaints of rectal bleeding. While hospitalized she received a transfusion of one unit of blood, ordered by the attending physician. Two months later, in January 1975, she was examined by her physician, who made a clinical diagnosis of hepatitis.2
The unit of blood administered to Miss Fisher, as a Red Cross representative testified, was collected from a volunteer donor in October 1974. At the time of donation, the blood was tested for type and group, as well as for hepatitis and syphilis contamination. The hepatitis test result was negative. The blood unit passed through the blood supply operations at Sibley Hospital and was retested for the hepatitis virus with negative results at the hospital laboratory facility. As was customary, the Red Cross charged a processing fee for the unit of blood which was paid by the hospital. Miss Fisher, in turn, was charged separately on an itemized hospital bill for blood processing and for the actual blood transfused. The charge for the blood was described as a “donor motivation fee” which was refundable if she later donated blood to the hospital.
There was conflicting expert testimony introduced at trial regarding the mode by which the hepatitis virus, Type A, is transmitted. Appellant’s treating physician and an expert medical witness called by appellant at trial both testified that Type A may be transmitted by blood transfusions, although the primary means of transmission is oral, through contaminated food or water. The expert medical witness called by the defendant, a physician affiliated with the hospital, testified that the Type A virus is believed to be transmitted orally, while Type B is linked to injections with contaminated needles and transfusions of impure blood.
Both experts testified, however, that no test will detect the presence of the Type A virus in the donor’s blood. The experts also agreed that an antigen test had been developed which discloses the presence of hepatitis Type B, but it is not totally accurate. Appellant’s medical expert placed the test’s accuracy as to Type B hepatitis at 70%, and at 35% overall accuracy as to carriers of [1132]*1132both types. According to appellee’s expert, the antigen test picks up about 30% of hepatitis carriers.
After argument, the court directed a verdict for defendant on the breach of warranty and strict liability theories, but denied the motion as to the negligence count. The negligence issue was submitted to the jury which returned a verdict for the hospital.
Under D.C.Code 1973, § 28:2-314, an implied warranty of merchantability arises from a contract of sale if the seller is a merchant with respect to the goods sold. Thus, to state a valid cause of action for breach of warranty, plaintiff first must demonstrate that the giving of. a blood transfusion constitutes a sale of goods carrying an implied warranty of fitness for ordinary uses. D.C.Code 1973 § 28:2-314(2)(c). In Perlmutter v. Beth David Hospital, 308 N.Y. 100, 123 N.E.2d 792 (1954), the first case to construe the implied warranty theory as applied to blood transfusions, the court held that plaintiff failed to state a cause of action. It reasoned that a blood transfusion could not be characterized as a product sold to the patient. Rather, the transfusion was a “service” which was part of the overall treatment that plaintiff received from the defendant hospital.
The “sales-service” dichotomy has controlled much of the hepatitis case law subsequent to Perlmutter.3 Its rationale — that blood transfusions are services for which breach of warranty will not lie — was not questioned until 1966 when the Florida Supreme Court in Community Blood Bank Inc. v. Russell, 196 So.2d 115 (Fla.1967), carved out an exception for commercial blood banks. Although the courts of various states have recently gone different ways in the blood transfusion cases,4 the majority are reluctant to apply traditional notions of sales law and the commercial warranty concept to nonprofit hospitals. As the Minnesota Supreme Court persuasively stated in dismissing a hepatitis victim’s suit:
We find it difficult to give literal application of principles of law designed to impose strict accountability in commercial transactions to a voluntary and charitable activity which serves a humane and public health purpose. The activities involved in the transfusion of whole blood, a component of the living body, from one human being to another may be characterized as sui generis in that the sequence of events involve acts common to legal, concepts of both a sale and a service. Moreover, it seems to us that under the facts in the case before us it would be unrealistic to hold that there is an implied warranty as to qualities of fitness of human blood on which no medical or scientific information can be acquired and in respect to which plaintiff’s physician has the same information, knowledge, and experience as the supplier. [Balkowitsch v. Minneapolis War Memorial Blood Bank, Inc., 270 Minn; 151, 132 N.W.2d 805, 811 (1965).]
[1133]*1133We agree with those courts which hold that the furnishing of blood is more in the nature of a service than of a sale of goods. Treating blood transfusions as an incidental service performed by hospitals comports with reality, and with the policies underlying merchantability liability. Although theoretically a seller’s inability to discover defects in the goods he sells is not relevant to a warranty cause of action,5 we cannot ignore the difficulty of detecting hepatitis in blood given the current state of medical knowledge.6 To characterize as a sale the supplying of blood would mean that the hospital, no matter how careful, would be held responsible, virtually as an insurer, if the patient were harmed as a result of impure blood. After balancing the safety of the individual with the interests of the hospital (in light of the absence of an adequate test to determine the presence of hepatitis in the blood) and the public interest in assuring the ready availability of blood for medical treatments, we are reluctant to extend § 2-314 merchantability liability to a nonsale transaction by analogy 7 or by characterizing the transaction as a sale.
Because we view actions for breach of warranty and strict liability in tort8 as being expressions of a single basic public policy as to liability for defective products, it would be inconsistent to hold that the doctrine of strict tort liability applies to blood transfusions while rejecting plaih-tiff’s breach of warranty claim. As this court has stated, “the current doctrines of implied warranty and strict liability in tort are but two labels for the same legal right and remedy, as the governing principles are identical.” Cottom v. McGuire Funeral Service, Inc., D.C.App., 262 A.2d 807, 808 (1970).
Several state courts recently have imposed strict tort liability upon blood suppliers,9 most notably Illinois in Cunningham v. MacNeal Memorial Hospital, 47 Ill.2d 443, 226 N.E.2d 897 (1970). The Cunningham approach has been criticized by other state courts, however, on the ground that the decision forecloses a balancing of dangers and benefits, making blood products vulnerable to strict liability without regard to social benefits. See, e. g., Hines v. St. Joseph’s Hospital, 86 N.M. 763, 527 P.2d 1075 (1974). Other courts have refused to label blood products “unreasonably dangerous” within the meaning of Restatement (Second) of Torts § 402A (1965), because the scientific inability to screen all carriers of viral hepatitis despite due care makes blood an unavoidably unsafe product. See Brody v. Overlook Hospital, 127 N.J.Super. 331, 317 A.2d 392, aff’d, 66 N.J. 448, 332 A.2d 596 (1974); Hines, supra; McMichael v. American Red Cross, 532 S.W.2d 7 (Ky.App. 1975). In Heirs of Fruge v. Blood Services, 506 F.2d 841 (5th Cir. 1975), the court found inapplicable to blood transfusions the rationale favoring the imposition of strict tort [1134]*1134liability10 (e. g., one who solicits and invites use of his product by advertising, representing it to be safe, ought to be held liable for injury to the person induced to purchase it), because blood products are unavoidably dangerous and the patient relies on the skill of his physician, rather than the supplier’s representations.
Significantly, Comment K to § 402A provides an exception to strict liability for products, drugs in particular, which in the present state of human knowledge, are incapable of being made safe for their intended and ordinary use (/. e., rabies vaccine), but where existing medical experience justifies the marketing and use of the product despite the risk. Restatement (Second) of Torts, supra at 353-54. Although the Cunningham court characterized blood containing hepatitis as impure and defective, and thus distinguishable from a rabies vaccine which poses an inherent danger even when properly prepared, we find such a reading of § 402A’s underlying policies unnecessarily cramped. As the court in Hines, supra, stated 527 P.2d at 1077, “the Cunningham court, by categorically limiting the applicability of the exception to ‘pure’ products stultified the flexible policy behind the exception.”
In light of the underlying policies of products liability law, characterizing blood plasma as a product governed by strict tort liability is as unnatural as forcing a blood transfusion into the commercial sales mold. The policy rationale for imposing strict liability upon beauty parlors, see Newmark v. Gimbel’s, Inc., 54 N.J. 585, 258 A.2d 697 (1969) (Article Two warranty provisions do apply to beauty treatments), or upon lessors of personal property, see Cintrone v. Hertz Truck Leasing and Rental Service, 45 N.J. 434, 212 A.2d 769 (1965), differs significantly from the policy considerations in a noncommercial context such as a hospital where the supplying of blood is subordinate to the main object of health care and treatment.
Accordingly, the directed verdict for defendant-hospital was correctly granted and the judgment is
Affirmed.